

ORAL SESSIONS

09.00–10.30

11.00–12.30

PL3 Plenary: Care and Treatment in 1998



Chairs: Awa Marie Coll-Seck, Gregg Gonsalvez
 Venue: Arena
 Time: 09.00–10.30

- 324 State-of-the-art: antiretroviral treatment in 1998
Julio Montaner
- 325 From scientific proof of efficacy to effectiveness in the real world
Wafaa El-Sadr
- 326 From scientific proof of efficacy to effectiveness in the real world
Bill Whittaker
- 327 Access: from basic care to state-of-the-art
Jorge Beloqui

A31 Humoral Immunity

Chairs: Gregory Hardy, Susan B. Zolla-Pazner
 Venue: Session Hall IV
 Time: 11.00–12.30

- 328 Humoral immunity
S. Zolla-Pazner, USA
- 329 HIV-1 specific mucosal IgA in a cohort of HIV-1 resistant Kenyan prostitutes 31101
Rupert Kaul; D. Trabattoni; J.J. Bwayo; D. Arienti; M. Clerici; F.A. Plummer, Kenya*
- 330 Study of the impact of neutralizing antibodies on the course of established infection with HIV-1 primary isolates in the hu-PBL-SCID mouse model 31103
Pascal Poignard; R.J. Gulizia; G. Picchio; M. Wang; P.W.H. Parren; D.E. Mosier; D.R. Burton, USA*
- 331 The antibody response in HIV-1 infection is directed against viral debris rather than virions 31104
Paul W.H.I. Parren; Q.J. Sattentau; D.R. Burton, USA*
- 332 Role of glycosylation in HIV-infection 21131
Cecilia Graziosi; S. Paolucci; M.B. Daucher; G. Centeno; A.S. Fauci; G. Pantaleo, Switzerland*

NOTES

B31 Clinical and Virologic Manifestation of HIV-infection		G
Chairs: Sushma Sengupta, Marcio Soares Serra		
Venue: Session Hall III		
Time: 11.00–12.30		
333	Primary HIV-1 infection: Clinical manifestations among women in Mombasa, Kenya <i>Ludo Lavreys*</i> ; <i>H. Martin</i> ; <i>K. Manoaliya</i> ; <i>J. Bwayo</i> ; <i>J. Nainya-Achola</i> ; <i>J. Kreiss</i> , Kenya	12186
334	Complete HIV pol sequence in plasma and genital tract of women: Genital reservoir and differential drug resistance <i>Guowei Fang*</i> ; <i>H. Burger</i> ; <i>K. Anastos</i> ; <i>C. Chappey</i> ; <i>D. Mayers</i> ; <i>W. Meyer</i> ; <i>B. Weiser</i> , USA	32279
335	Repertoire of chemokine receptor expression in the female genital tract: Progesterone increases CCR5, CXCR4, and CCR3 expression <i>Bruce Patterson*</i> ; <i>A. Landay</i> ; <i>J. Andersson</i> ; <i>H. Behbahani</i> ; <i>M.A. Czerniewski</i> ; <i>Z. Burki</i> ; <i>P. Garcia</i> , USA	21109
336	Alterations in body fat distribution in HIV-infected men and women <i>Donald P. Kotler*</i> ; <i>K.B. Rosenbaum</i> ; <i>J. Wang</i> ; <i>R.N. Pierson, Jr.</i> , USA	32173
337	Determinants of increased energy expenditure in HIV-infected women <i>Steven K. Grinspoon</i> , USA	32162
338	Immunologic function and reconstitution in HIV-infected patients on highly active antiretroviral therapy (HAART) <i>Ilana Fogelman*</i> ; <i>V.J. Davey</i> ; <i>M. Sneller</i> ; <i>M.B. Feinberg</i> ; <i>H.D. Ochs</i> ; <i>J.P. Siegel</i> ; <i>H.C. Lane</i> , USA	31186

B32 Clinical Immunology in HIV-1 Infection		
Chairs: Adriano Lazzarin, Kiat Ruxrungtham		
Venue: Session Hall VII		
Time: 11.00–12.30		
339	Triple combination therapy and change in peripheral blood T-cell subset composition during asymptomatic HIV-infection <i>Leslie R. Bisset*</i> ; <i>Milos Opravil</i> ; <i>R. Con</i> ; <i>W. Huber</i> ; <i>M. Battegay</i> ; <i>P. Vernazza</i> ; <i>P.J. Grob</i> ; <i>R. Luethy</i> , Switzerland	41178
340	Immune restoration disease after treatment of immunodeficient HIV-infected patients with potent antiretroviral therapy <i>Martyn French*</i> ; <i>N. Lenzo</i> ; <i>M. John</i> ; <i>S. Mallal</i> ; <i>P. Price</i> ; <i>J. Flexman</i> , Australia	22323
341	Extended benefit of protease inhibitor-containing combination therapy through a dissociated viremia-CD4 T cell response <i>Daniel Kaufmann*</i> ; <i>Giuseppe Pantaleo</i> ; <i>Pascal Meylan</i> ; <i>Philippe Sudre</i> ; <i>Patrick Francioli</i> ; <i>Micheal P. Glauser</i> ; <i>Amalio Telenti</i> , Switzerland	12101
342	Discrepant immunologic and virologic responses in HIV-infected patients receiving triple combination therapy <i>Christophe Piketty*</i> ; <i>P. Castiel</i> ; <i>L. Belec</i> ; <i>L. Weiss</i> ; <i>J.P. Abouker</i> ; <i>M.D. Kazatchkine</i> , France	32259
343	IL2 in HIV patients: A randomized trial comparing SC, PEG, CIV IL2 with AZT + ddI <i>Yves Levy*</i> ; <i>C. Capitant</i> ; <i>S. Houhou</i> ; <i>I. Carriere</i> ; <i>J.A. Gaustaut</i> ; <i>J.P. Viard</i> ; <i>J.P. Aboulker</i> , France	41229
344	Long-term follow-up of an early HIV-infected cohort receiving intermittent outpatient treatment with subcutaneous interleukin-2 (sclL-2) <i>Richard Davey, Jr. *</i> ; <i>D.G. Chaitt</i> ; <i>J.A. Kovacs</i> ; <i>R.E. Walker</i> ; <i>J. Falloon</i> ; <i>M.A. Polis</i> ; <i>H.C. Lane</i> , USA	41230
345	Changes in lymphocyte subsets with interleukin-2 therapy in patients with advanced HIV disease on highly active antiretroviral therapy (HAART) <i>Daniel Berger*</i> ; <i>B.E. Baker</i> ; <i>G. Bucher</i> ; <i>R. Bessinger</i> ; <i>P. Maroni</i> ; <i>W.M. Reiter</i> , USA	22412
346	In vivo persistence of genetically modified, HIV-1-specific syngeneic lymphocytes in HIV-1-discordant identical twins <i>Robert Walker*</i> ; <i>C.M. Bechtel</i> ; <i>V. Natarajan</i> ; <i>R.M. Blaese</i> ; <i>K.M. Hege</i> ; <i>M.R. Roberts</i> ; <i>H.C. Lane</i> , USA	42322

B33 Current Limits and Future of ART		P
Chairs: Ibrahim Ndoye, Eric Van Praag		
Venue: Arena		
Time: 11.00–12.30		
347	Barriers to therapeutic effectiveness of ART <i>Claudia Brabazon</i>	
348	Issues in clinical management in middle income settings <i>Pedro Cahn</i>	
349	Implications of ART use in resource-poor settings <i>Elly Katabira</i>	
350	The future of HIV therapy <i>Daniel Kuritzkes</i>	
C31 Forecasting and Determinants		
Chairs: Ronald Brookmeyer, Kofi Awusabo-Asare		
Venue: Session Hall V		
Time: 11.00–12.30		
351	Forecasting the global pandemic: use and misuse of data <i>Tim Brown</i>	
352	Epidemic determinants and dynamics in Africa <i>To be announced</i>	
353	Concepts and models: sexual networks and population groups <i>Richard Rothenberg</i>	
354	Cost and impact of interventions on epidemic dynamics <i>Charlotte Watts</i>	
C32 Local Policies, National Issues, Global Impact		P
Chairs: Dennis P. Altman, Rao Prasad		
Venue: Session Hall VI		
Time: 11.00–12.30		
355	HIV/AIDS policy in Brazil <i>Richard G. Parker*</i> ; <i>J. Galvao</i> , USA	43560
356	Setting performance standards for a national HIV prevention program <i>David R. Holtgrave*</i> ; <i>S. Pinkerton</i> , USA	43500
357	A public health approach to move HIV prevention research to practice <i>Jane Mezzoff*</i> ; <i>E. Sogolow</i> ; <i>L.S. Doll</i> ; <i>S. Semaan</i> ; <i>M.S. Neumann</i> ; <i>J.R. Anderson</i> , USA	43218
358	Medical supply for HIV/AIDS in developing countries: Thailand experience <i>Chaiyos Kuananusont*</i> ; <i>P. Satsit</i> ; <i>W. Phoolcharoen</i> , Thailand	43506
359	Enhancing training capacities through regional military networking in countries of Eastern and Southern Africa <i>Joyce Chiluba Puta</i> , Zambia	43391
360	Integrating AIDS prevention into family planning program in southern Yunnan, China <i>Zunyou Wu*</i> ; <i>J.P. Zhang</i> ; <i>C.M. Wang</i> ; <i>L.L. Dong</i> ; <i>X.Q. Bi</i> ; <i>S. Duan</i> ; <i>Z.R. Li</i> , China	13403

C33 Recent Diffusion of Drug Injecting: Identification and response **H**

Chairs: Sujata Rana, Alex Wodak
 Venue: Satellite Hall 2000
 Time: 11.00–12.30

- 361 Diffusion of injecting drug use in transitional societies: Russian Federation and newly independent states
Lev Khodakevich
- 362 Spread of injecting drug use in South and Southeast Asia developing: Asian harm reduction network
Palani Narayan
- 363 Community-based programmes to prevent the spread of injecting drug use
Suresh Kumar
- 364 Potential spread of injecting drug use into high vulnerability populations in West Africa
Moruf Adelekan
- 365 Rapid assessment methods and intervention development for injecting and HIV-infection
Gerry Stimson
- 366 Injecting drug users' viewpoints
Annie Madden

D31 Panel: Approaches to Women-Centered Prevention **G**

Chairs: Suzanne Desbiens, Purnima Mane
 Venue: Session Hall I
 Time: 11.00–12.30

- 367 Overview: issues and challenges in female-controlled prevention
Maxine Ankras
- 368 Empowering women: meeting the challenge in a clinical setting
Erica Gollub
- 369 Responding to reality: integrating family planning and STD prevention post-ICPD
Jodi Jacobson

D32 Involving the Community in HIV/AIDS Prevention and Care **P**

Chairs: Mary Crewe, S. Sundararaman
 Venue: Session Hall II
 Time: 11.00–12.30

- 370 Introduction
Jeffrey O'Malley
- 371 Strengthening the community response to the HIV epidemic in Senegal 34120
Elizabeth Reid; Moustapha Gueye; B. Goumbala, Senegal*
- 372 Mobilization of communities for social change through risk behaviour mapping 13408
Hendrikus Schapink; Jenance Nyomyo, Tanzania*
- 373 Community-based care for people living with HIV/AIDS 34140
Pimjai Intamoon, Thailand
- 374 Integration of HIV/AIDS prevention and care at a community level 34109
Ronaldo Mussauer De Lima; A.V.S. Menezes; E.T. Santos-Filho; R.S. Ramos; H.C. Guerreiro, Brazil*
- 375 Discussant
Smarajit Jana; S. Popov, India*

Skills-Building Workshops 11.00–14.30: see page 00 for details

A32 Molecular Biology/New Targets

Chairs: Lutz G. Gurtler, Ramond F. Schinazi
 Venue: Session Hall III
 Time: 13.00–14.30

- 376 Inhibition of HIV-1 reverse transcription by actinomycin D (Act D): A potential approach for AIDS therapy 11124
Judith G. Levin; J. Guo; T. Wu; J. Bess; L.E. Henderson, USA*
- 377 HIV-1 Vif is an endogenous inhibitor of HIV-1 protease and peptide derivatives of Vif inhibit Gag-Pol processing and HIV-1 replication 11130
David Volsky; P. Sova; M. Simm; C. Krachmarov; T. Muir; R.J. Potash, USA*
- 378 Compensatory point mutations in the HIV gag region that are distal from deletion mutations in the dimerization initiation site can restore viral replication 11126
Mark A. Wainberg; Chen Liang; Liwei Rong, Canada*
- 379 The impact of interactions between NC, viral RNA and protease of HIV-1 on infectious virion assembly 11131
Susan Erickson-Viitanen; D. Ozturk; H.K. Choi; R. Tritch; R. Meade; A. Draganescu; P. Cawood, USA*
- 380 Quantitative molecular analysis of RNA expression of HIV-infected T cell using high density oligonucleotide arrays 11139
Jacques Corbeil; T.R. Gingeras; G. Mamtora; D. Huang; D.D. Richman, USA*
- 381 Molecular mechanisms of HIV-1 nuclear import: MA and Vpr are the key regulators 11144
Michael Bukrinsky; S. Popov, USA*

A33 Viral Reservoirs

Chairs: Francoise F. Brun-Vézinet, Soleymane Mboup
 Venue: Session Hall VII
 Time: 13.00–14.30

- 382 Lymphocytes and lymph nodes
Ashley Haase
- 383 Dendritic cells
Melissa Pope
- 384 HIV and macrophages
Jan Orenstein

NOTES

B34	Clinical Care of Women with HIV	G
Chairs: Ken Mayer, Junsuda Suwunjundee		
Venue: Session Hall IV		
Time: 13.00–14.30		
385	Gynaecological conditions in HIV-positive women <i>Anne Duer</i>	
387	Treatment of HIV-infection in pregnancy <i>Kathleen Squires</i>	
388	Clinical care of women in the South <i>Elizabeth Madraa</i>	
B35	Adherence to ART: New Research	
Chairs: Gerald H. Friedland, Phapan Phanupak		
Venue: Arena		
Time: 13.00–14.30		
389	Strategies to optimise adherence to highly active antiretroviral treatment <i>Hernando Knobel*</i> ; <i>A. Carmona</i> ; <i>S. Grau</i> ; <i>P. Saballs</i> ; <i>J.L. Gimeno</i> ; <i>J.L. Lopez Colomes</i> , <i>Spain</i>	32322
390	Protease inhibitors (PI) in the HIV+ homeless and marginally housed (H/M): Good adherence but rarely prescribed <i>David Bangsberg*</i> ; <i>M. Robertson</i> ; <i>E. Charlebois</i> ; <i>J. Tulsy</i> ; <i>F.M. Hecht</i> ; <i>J. Bamberger</i> ; <i>A.R. Moss</i> , <i>USA</i>	32406
391	Interventions and patient outcome from a pharmacist-based HIV medication adherence referral clinic <i>Kathleen Graham*</i> ; <i>L.H. Beeler</i> ; <i>S. Renae</i> ; <i>M.G. Sension</i> , <i>USA</i>	32323
392	History of drug use and adherence in HIV+ persons <i>J.G. Turner*</i> ; <i>K.M. Nokes</i> ; <i>I.B. Corless</i> ; <i>W.L. Holzemer</i> ; <i>J. Inouye</i> ; <i>M.A. Brown</i> ; <i>G.M. Powell-Cope</i> , <i>USA</i>	32366
393	Adherence to currently prescribed antiretroviral therapies: Results from a multisite interview project <i>Jeffrey L. Jones*</i> ; <i>Allyn K. Nakashima</i> ; <i>D.A. Burgess</i> ; <i>J.W. Ward</i> , <i>USA</i>	32326
394	Increasing active drug users' adherence to HIV therapeutics (supported by the National Institute on Drug Abuse R01 08014) <i>Robert Broadhead*</i> ; <i>D.D. Heckathron</i> ; <i>P.G. O'Connor</i> ; <i>P.A. Selwyn</i> , <i>USA</i>	32336
C34	Bridging Session: Challenges to Implementing STD Prevention and Care	
Chairs: Antonio Gerbase, Marie Laga		
Venue: Session Hall V		
Time: 13.00–14.30		
395	From assessment to action <i>Francis Ndowa</i>	
396	Integrating STD programmes into primary health care <i>Cesar Nuñez</i>	
397	Involving non-public service providers <i>Mridula Sainath</i>	
398	Challenges in industrialised settings <i>Judy Wasserheit</i>	
399	Strategies for asymptomatic STDs <i>Gina Dallabetta</i>	
400	Discussant <i>Thia Phalia</i>	
C35	Culture and Community: Men Who Have Sex With Men	

Chairs: Julian Jayaseelan, Paolo Longo		
Venue: Session Hall VI		
Time: 13.00–14.30		
	G H	
401	Male sex work in Mexico City <i>Peter Aggelton*</i> ; <i>Ana Luisa Liguori</i> ; <i>Juan Jacobo Hernandez</i> , <i>Mexico</i>	23596
402	Being gay or what? Gender blinding among Filipino commercial sex workers and its implications on HIV/AIDS transmission <i>Oliver Patiño</i> , <i>The Philippines</i>	14233
403	Responding to the needs of Maori gay men and transsexuals who live in Sydney <i>Clive Aspin</i> , <i>New Zealand</i>	14220
403.1	HIV intervention among Chinese MSM in Hong Kong's "gay saunas" <i>Graham Donald Smith</i> , <i>Hong Kong</i>	43316
404	Human rights advocacy: Ensuring HIV/AIDS prevention among transvestite sex workers and other gay men in Guatemala <i>Rubén Mayorga</i> , <i>USA</i>	44146
405	Holistic workshops. Prevention of sexual transmission diseases (STD) and HIV/AIDS in vulnerable populations: Men that have sex with men <i>Luis Gauthier*</i> ; <i>Pablo Roberto</i> ; <i>Claudia Rodriguez</i> , <i>Chile</i>	43277
C36	Harm Reduction Programmes for IDUs	
Chairs: Pat O'Hare, Werarit Sittitrai		
Venue: Satellite Hall 2000		
Time: 13.00–14.30		
406	Needle exchange-based health services as a comprehensive community prevention program <i>Frederick Altice*</i> ; <i>K. Khooshnood</i> ; <i>K.M. Blankenship</i> ; <i>M.P. Lamberti</i> ; <i>P.A. Selwyn</i> , <i>USA</i>	43227
407	HIV/AIDS prevention activity among intravenous opioids users in Klaipeda (Lithuania) <i>Aleksandras Slatvickis</i> , <i>Lithuania</i>	23220
408	Harm reduction and community mobilisation with IDUs on Bangladesh/Indian border <i>Mahboda Akhter Kabita</i> , <i>Bangladesh</i>	33386
409	The impact results of a peer-driven intervention to combat HIV among drug injectors <i>Robert Broadhead*</i> ; <i>D.D. H.</i> ; <i>R.J. J.</i> , <i>USA</i>	33335
410	A simple method for process evaluation of needle-and-syringe-exchange programs: Results of pilot testing in Poland, 1997 <i>Philip Akabes*</i> ; <i>M. Beniowski</i> ; <i>M. Zygodlo</i> ; <i>E. Bozek</i> ; <i>G. Widowski</i> ; <i>J.P.C. Grund</i> , <i>USA</i>	23178
411	Implementing a harm reduction program (HRP) in the complex environment of Rio de Janeiro City <i>P.R. Telles*</i> ; <i>C.M. Sampaio</i> ; <i>W. Bastos, Jr.</i> , <i>Brazil</i>	33390

D33 Stigma and Discrimination		H	P
Chairs: Philippa Lawson, Paul Toh			
Venue: Session Hall I			
Time: 13.00–14.30			
412	Stigma associated with trial participation <i>Kathleen Mac Queen</i>		
413	Predictors for not currently receiving protease inhibitor therapy: Results from a multisite interview project <i>Jeffrey L. Jones*; Allyn K. Nakashima; D.A. Burgess; J.W. Ward, USA</i>	42282	
414	Circumstances of diagnosis of HIV-infection in Belo Horizonte, Brazil <i>Marcelo A. Campos, Brazil</i>	42228	
415	Legal provision for clients with HIV <i>Aurom Sherr, USA</i>	44116	
416	AIDS stigma and HIV-related beliefs in the United States: Results from a national telephone survey <i>Gregory Herek*; J.P. Capitanio, USA</i>	44173	
417	AIDS Stigma: A persistent social phenomenon in Mwanza, Tanzania <i>Soori Nnko, Tanzania</i>	34159	

D34 Taking Care of the Future: Support for Orphans		P	Y
Chairs: Dorothy Achieng Odhiambo, Niklas Bwakira			
Venue: Session Hall II			
Time: 13.00–14.30			
418	Evaluation criteria of foster care of HIV affected children <i>Oletto Serenella*; M. Vigolo; S. Giroto; C. Giaquinto, Italy</i>	34238	
419	AIDS orphans in direct support <i>Rose Florence Atibuni Drop*; Alia Penin Ah; Mary Andiandu; Alice Olea, Uganda</i>	13373	
420	Children of the cities – A situation analysis of urban orphans due to AIDS in Bulawayo <i>Stefan Germann*; Judith Mthombeni, Zimbabwe</i>	34174	
421	Preventing displacement of children orphaned by AIDS in Brazil <i>Miguel Fontes, Brazil</i>	24220	
422	AIDS orphans in Nairobi slums <i>Charles Thumi*; G.E. Horsfield, Kenya</i>	24219	
423	Discussant <i>To be confirmed</i>		

A34 Immune Responsiveness and Reconstitution	
Chairs: Gunnel Biberfeld, Paul A. Volberding	
Venue: Session Hall III	
Time: 15.00–17.00	
424	How HIV defeats the immune system <i>Rafick Sekaly</i>
425	Immune events in early HIV-infection <i>Bruce Walker</i>
426	Immune responses and reconstitution <i>Brigitte Autran</i>
427	Cytokines <i>Cliff Lane</i>

A35 Molecular Epidemiology		
Chairs: Francine E. MacCutchan, Son Nkeng		
Venue: Session Hall IV		
Time: 15.00–17.00		
428	Overview molecular epidemiology <i>F. McCutchan</i>	
429	Genetic recombination of HIV-1 strains identified in China <i>Yiming Shao*; L. Su; F. Zhao; H. Xing; Y.Z. Zhang; H. Wolf; L.L. Zhang, PR China</i>	11179
430	Molecular epidemiology of HIV-1 genetic subtypes in West and Central Africa <i>Martine Peeters*; E. ESU-Williams; E. Nzila; E. Mpoudi; Cameroun Yaounde; S. Mboup; S. Saragosti; E. Delaporte, France</i>	11163
431	The molecular epidemiology of HIV-1 in Uganda <i>Robert Downing*; B. Biryahwaho; R.A. Otten; M.A. Rayfield; D. Pieniazek; D. HU; S.D.K. Sempala, USA</i>	13109
432	HIV-1 group M and HIV-1 group O co-infections in Cameroon <i>Leopold Zekeng*; J. Takehisa; C. Kuaban; E. Afaneze; M. Hayami; L. Kaptue; L. Gurtler, Cameroon</i>	11187
433	Variability of HIV-2 from patients living in France <i>Francois Simon*; F. Damond; I. Loussert-Ajaka; C. Apetrei; D. Descamps; G. Collin; F. Brun-Vezinet, France</i>	11205
434	HIV-1 subtypes circulating in São Paulo, Brazil <i>Luis F.M. Brigido*; M. Rossini; I. Santos; Santana; C. Oliveira, Brazil</i>	13162
435	Inter-subtype recombinant strains of HIV-1 are frequently found among new full length sequences <i>Tiina Laukkanen*; W. Janssen; J. Carr; J. Albert; P.O. Leinikki; F.E. McCutchan; M.O. Salminen, Finland</i>	11170
436	Correlation between risk factors for HIV-infection in Russia and HIV-1 subtypes isolated in Russia in 1994–1997 <i>Natalia N. Ladnaia*; V.V. Pokrovski; A.F. Bobkov; I.G. Savchenko; L.M. Selimova; E.V. Kazennova; A.V. Kravtchenko, Russia</i>	13206

NOTES



B36 **Effects and Use of Antiretroviral Therapy** **H**
 Chairs: Roberto Badaro, Yves Mouton
 Venue: Session Hall VII
 Time: 15.00–17.00

- 437 Regional survival differences across Europe in HIV-positive patients reflect differences in antiretroviral treatment. Data from the EuroSIDA study group
*Stefano Vella**; Antonio Chiesi; L.G. Dally; A. Macroft; A.N. Phillips; V. Miller; S. Stazewski; Jens D. Lundgren, Italy 12272
- 438 Changes in use of antiretroviral therapy in regions of Europe over time: The EuroSIDA Study
Jens D. Lundgren, Denmark 22335
- 439 Preliminary comparison of outcome in patients starting either ritonavir (R), indinavir or saquinavir (S) in 1749 patients from the EuroSIDA study
Jens D. Lundgren, Denmark 12273
- 440 Clinical progression and adverse events in a cohort of HIV-infected patients with advanced immunodeficiency started on protease inhibitors (PI) in March 1996
*Genevieve Chene**; C. Katlama; J.P. Coulaud; R. Lasalle; J.M. Ragnaud; C. Lepout, France 12266
- 441 Mortality and health care costs for 6,297 AIDS patients in California before and after protease inhibitors
*Mi Chen**; J. Rains; G. Hiehle; R. Hun; J. Colford, USA 12264
- 442 Changes in HIV/AIDS patterns of care and estimated costs at an urban medical center during the era of HAART
*James E. Rawlings**; J. Holmes; B. Belton; P. Selwyn; G. Friedland, USA 42430
- 443 Inversion of inpatient/outpatient HIV service utilization: Impact of improved therapies, clinician education and case management in the US Department of Veteran Affairs
*Abid Rahman**; L.R. Deyton; M.B. Goetz; D. Rimland; M.S. Simberloff, USA 42429
- 444 One world, one hope: The cost of making antiretroviral therapy available to all nations
*Robert Hogg**; K.J.P. Craib; A. Weber; A. Anis; M.T. Schechter; J.S.G. Montaner; M.V. O'Shaughnessy, Canada 42283
- 445 Assessment of eligibility for antiretroviral therapy among HIV- infected patients attending selected outpatient clinics in Abidjan, Côte d'Ivoire
*Gaston Djomand**; J. Nkengasong; M. Sassan-Morokro; R.A. Ekpini; P.D. Ghys; O. Tossou; C. Maurice; S. Konate; T.H. Roels; A.E. Greenberg; S.Z. Wiktor, Côte d'Ivoire 42291
- 446 Why is highly active antiretroviral therapy (HAART) not prescribed or why is it discontinued – A prospective analysis in the Swiss HIV cohort study (SHCS)
*Stefano Bassetti**; Manuel Battegay; M. Rickenbach; M. Flepp; H.J. Furrer; A. Telenti; P. Vernazza; E. Bernasconi; P. Sudre, Switzerland 32335

NOTES

B37 **Tuberculosis: Prevention and Management**
 Chairs: Kenneth Castro, Daniel Kibuga
 Venue: Arena
 Time: 15.00–17.00

- 447 A randomized trial of rifampin/pyrazinamide for 2 months vs. INH for 12 months in HIV+, tuberculin+ adults (CPCRA004/ACTG177/CDC/PAHO)
*Richard E. Chaisson**; F. Gordin; J. Matts; L. Garcia; R. Hafner; R. O'Brien, USA 22126
- 448 Adherence and compliance in tuberculosis preventive therapy trial at the JCRC in Uganda
*Mary Nasira Mulindwa**; D. Tumukunde; M.W. Kiyimba; K.A. Byamukama; M.S. Wanyana; K. Kataliwa; C. Opiit, Uganda 22129
- 449 Feasibility of preventive therapy of tuberculosis for HIV-infected subjects – GISTA Study
*Giorgio Antonucci**; Giuseppe Ippolito, Italy 13261
- 450 Cost-effectiveness of isoniazid preventive therapy for HIV-infected people in sub-Saharan Africa
*Jensa Bell**; Henry Sacks; D.N. Rose; H.S. Sacks, USA 13278
- 451 Isoniazid prophylaxis for tuberculosis in HIV-infection: A meta-analysis of randomized controlled trials
*Heiner C. Bucher**; M. Naef; L.D. Griffith; P. Sudre; M. Battegay, Switzerland 22124
- 452 Increasing burden of tuberculosis and high rate of drug resistance in an HIV epicenter in Northern Thailand, 1989–1997
*Somsak Supawitkul**; T. Yoshima; D. Rienthong; P. Akarasevi; N. Kunyanone; S. Saisorn; H. Yanai, Thailand 22131
- 453 How likely are TB patients to be accurately diagnosed in urban health centres in Lusaka, Zambia?
*Joseph Kamanga**; Peter Godfrey-Faussett; H. Kaunda; A. Kambashi; M. Van Cleef; V. Tihon, Zambia 22154
- 454 Ethambutol (EMB) in the continuation phase of tuberculosis (TB) treatment in HIV-1 infected Ugandan adults
*Alphonse Okwera**; J.L. Johnson; P. Nsubuga; C. Whalen; D.L. Cohn; R. Mugerwa; J. Ellner, Uganda 22140

B38 **The 1998 Treatment Guidelines IAS/USA**
 Chairs:
 Venue: Satellite Hall 2000
 Time: 15.00–17.00

C37 Mother-to-Child HIV Transmission: New findings		P	Y
Chairs: Ruth Wanjitzu Nduati, Ruth Webb			
Venue: Session Hall V			
Time: 15.00–17.00			
456	Late postnatal mother-to-child transmission (LPT) of HIV-1: International multicentre pooled analysis <i>Valeriane Leroy*; M.L. Newell; F. Dabis; C. Peckham, France</i>	23266	
457	HIV-infection due to breastfeeding in a cohort of babies not infected at enrollment <i>Taha Taha*; P. Miotti; N. Kumwenda; H. Van Der Hoeven; D. Markakis; D. Hoover; R. Biggar, USA</i>	23270	
458	Control of maternal HIV-1 disease during pregnancy <i>Karen Beckerman*; M. Benson; S. Dahud; M. Shannon, USA</i>	12151	
459	Missed opportunities to reduce perinatal HIV transmission: Maternal and neonatal zidovudine (ZDV) use in Los Angeles county (LAC) <i>Laurene Mascola*; Toni Frederick; J. Jackson; Y.S. Shin; A. Kovacs; J. Bertolli, USA</i>	23273	
460	Health care providers' awareness of the ACTG 076 findings and their adherence to government guidelines to reduce perinatal transmission of HIV <i>Kaenan Hertz*; D. Parham; L. Soto-Torres; S. Trent-Adams, USA</i>	42210	
461	Association between placental malaria infection and increased risk of mother-to-infant transmission of HIV-1 in western Kenya <i>Bernard Nahlen*; Richard Steketee; J. Ayisi; A. Van Eijk; J. Otieno; A. Misore; M. Rayfield; K. Udhayakumar, USA</i>	23268	
462	Risk factors for perinatal HIV transmission in women/infants receiving standard zidovudine (ZDV) prophylaxis <i>John Lambert*; L. Mofenson; E.R. Stiehm; J. Bethel; W. Meyer; P. Reichelderfer; G. Nemo, USA</i>	23265	
463	Combination therapy with nevirapine, zidovudine and a second nucleoside analog during pregnancy <i>Francoise Kramer*; A. Stek; J. Homans; M. Khoury; A. Kovacs, USA</i>	12152	

C38 Male and Female Condoms		G
Chairs: Monir Islam, Brenda Spencer		
Venue: Session Hall VI		
Time: 15.00–17.00		
464	The condom user: ensuring the safety and acceptability of the product <i>John Gerofi</i>	
465	The would-be condom user: making the right product available at the right time <i>Patrick Friel</i>	
466	Free condoms/sold condoms: Which is actually used? Lessons from the field in a remote district of Northern Uganda <i>Jacques Homsy*; J.W. Idro; S. Tani; A. Odule; I. Juma; R. King; D. Schopper, Uganda</i>	14263
467	Analysis of unit costs in 23 condom social marketing programs 1990–1996 <i>Guy Stallworthy, USA</i>	44240
468	Challenges to female condom intergration into condom programming <i>Chuanchom Sakindhavat</i>	
469	The promise of female-controlled methods: Zimbabwe experience of social marketing of female condom <i>Tsitsi Tsopotsa</i>	
470	New perspectives for condoms <i>James McIntyre</i>	

D35 Bridging Session: Ethics and Science		H	P	Y
Chairs: Nobert Gilmore, June E. Osborn				
Venue: Session Hall I				
Time: 15.00–17.00				
471	Additional unethical aspects of vertical transmission studies in developing countries <i>Peter G. Lurie*; S.M. Wolfe, USA</i>	44123		
472	Reply <i>Hoosen Coovadia</i>			
473	Developing policies on HIV/AIDS and pregnancy that respect law, ethics and human rights <i>Lori Stoltz*; L. Shap; R. Jurgens, Canada</i>	44101		
474	Ethics in HIV/AIDS research in Kenya. The cases of Immunex, Kemron, Pearl Omega and Polyatomic Capheresis (WDDS treatment) <i>Ambrose Rachier, Kenya</i>	44140		
475	Ethical vs moral duties when HIV/AIDS clinical trials end <i>Jose Luis Valdespino Gomez*; M.L. Garcia Garcia; M. Palacios Martinez; L. Ferreyra Reyes; M.E. Mayar Maya; M.E. Jimenez Corona; M. Ramos Madrigal, Mexico</i>	44126		
476	Providing care, support and treatment to HIV-positive injection drug users: Legal and ethical issues <i>Eugene Oscapella*; R.E.F. Jürgens; D. Rilley; D. Roy; T. De Bruyn; E. Burnham, Canada</i>	44135		

D36 Resource Allocation: How to Get the Most Out of Limited Resources?		P
Chairs: Wences Msuya, Wiputh Poolcharoen		
Venue: Session Hall II		
Time: 15.00–17.00		
477	Costing HIV using an observation database <i>Dale Mc Murchy*; M. Millson; K. Leeb; RWH. Palmer; G. Robinson; A. Rachlis; R. Wall, Canada</i>	24127
478	The impact of HIV/AIDS on the health sector in Uganda <i>Harold Michael Jjemba*; E. Madraa; T. Lutalo, Uganda</i>	43497
479	The cost-effectiveness of prophylaxis for mycobacterium avium complex in AIDS <i>Kenneth Freedberg*; J.A. Scharfstein; G.R. Seage, III; E. Losina; M.C. Weinstein; D.E. Craven; A.D. Paltiel, USA</i>	44238
480	Costing HIV/AIDS: The Canadian HIV/AIDS economic research initiative <i>Janet Dubrack*; T. Albert; B. Jones; J. Martin; R. Shearer; G. Williams, Canada</i>	24122
481	The affordability of antiretroviral therapy in developing countries: What policymakers need to know <i>Steven Forsythe, UK</i>	44245
482	Expansion of U.S. medicaid system to cover HIV drugs will prevent thousands of deaths and AIDS diagnoses, and is affordable <i>James G. Kahn*; B. Haile; S.W. Chang, USA</i>	44241
483	Home-based nursing care: The cost effective way <i>Lorna Scheepers, South Africa</i>	22466
484	Implicit valuation of a blood exclusion decision <i>Edward H. Kaplan*, USA</i>	44244

Skills Building Workshops 15.00–18.30: see page 00 for details

CS 11 Alternative and Traditional Healing Practices
Venue: Session Hall I
Time: 17.30–20.00

Short presentations by an expert panel, followed by separate group discussion of each topic, and then plenary discussion of a declaration/recommendations and the possible formation of a network.

Chairs
Kaiya Montaocean, The Center for Natural and Traditional Medicines, USA
Xevi Garcia Floris, Plataforma NATC and ACTUA, Spain

- Speakers**
- Research and traditional medicine
Donna Kabatesi, THETA, Uganda
 - Traditional and herbal medicines: examples of what is being used and requested in selected communities
Merci Manci, South Africa
 - Collaboration between traditional and modern medical practitioners
Erick Gbodossou, Senegal
 - Life philosophy and spiritual practices
Dorjee Rapten Neshar, Tibetan Medical and Astro Institute, India

- Group Facilitators**
- *Luke Kwamya, THETA, Uganda*
 - *Lynde Francis, Director, The Center, Zimbabwe*
 - *Edward Green, USA*
 - *Jamie McHugh, USA/ Switzerland*

CS 12 AIDS, Human Rights and Activism H
Venue: Session Hall II
Time: 17.30–20.00

Two keynote speeches, followed by small group work considering case studies, and back to plenary session for report back, recommendations, and discussion of the role of International Guidelines on HIV/AIDS and Human Rights.

Chairs
Bai Bagasao, Programme Development Officer, Department of Country Support, UNAIDS
Florian Hübner, Executive Director, Groupe SIDA Genève, Switzerland

- Speakers**
- The perspective of a human rights activist
To be announced
 - The perspective of an AIDS activist
Mark Heywood, Head, AIDS Law Project, South Africa

NOTES

CS 13 Are World AIDS Conferences Worth It? P
Venue: Session Hall III
Time: 17.30–20.00

Interactive roundtable exploring, from five different perspectives, the overall impact of a World AIDS Conference and its role in relation to other international scientific conferences and to regional AIDS conferences.

Chairs
Richard Burzynski, Executive Director, ICASO, Canada
David Cooper, IAS President, Australia

- Speakers**
- Impact on the world's media, and consequent public understanding of HIV/AIDS
Laurie Garrett, Newsday, USA
 - Are world AIDS conferences different and useful compared with other international clinical meetings?
Ian Weller, The Mortimer Centre, UK
 - The role of regional AIDS conferences versus a world AIDS conference
To be announced
 - Analysis of the economic impact of world AIDS conferences
Stefano Bertozzi, Switzerland, Pharmaceutical company representative WHL (Chip) Lindner, Senior Adviser to the Chairman 12th World AIDS Conference, Switzerland

CS 14 Positive Prevention: the Role of HIV+ People in Prevention
Venue: Session Hall IV
Time: 17.30–20.00

Presentations from a number of perspectives, followed by small group discussion on some of the issues.

Chairs
René Lavoie, Action Sero-Zero, Canada
River Huston, ICW, USA

- Speakers**
- Positive prevention in the Pacific Islands
Colleen Perez, Palao'an Plus, Guam
 - The involvement of people with HIV in developing government operations and programmes
Gary Scott, The Terrence Higgins Trust, UK
 - Positive people's education with self esteem leading to better outcomes in prevention
Andrew Little, Communications Officer, NAPWA, Australia
 - The 'Faces' Project
Beatrice Were, NACWOLA, Uganda
 - Projet-Ecole: bringing positive lives to school and beyond
Christopher Park, Positive Speakers Group, Swiss AIDS Federation, Switzerland
 - The Soweto HOPE model
Emily Mabote, Soweto HOPE Programme, South Africa
 - Mobilising positive people in an unsupportive environment
Anuar Luna-Cadena, Colectivo Sol, Mexico

COMMUNITY SYMPOSIA

17.30–20.00

CS 15 AIDS and Media Responsibility

Venue: Session Hall VI
Time: 17.30–20.00

'Talk show presentation' with a panel of respondents. Pertinent and controversial questions will be posed by the host to the panel, who will encourage dialogue and challenge them on responses given, as well as involve and encourage audience participation. This symposium aims to encourage community activists to develop working partnerships with the media, and to explore some constraints in practice. However, the session is intended to be both entertaining and informative.

Host

Cheryl Caroules, South African Ambassador to the UK

Panellists

George Strait, ABC News, USA

Javier Luis Hourcade Bellocq, Argentina

Larry Altman, NY Times, USA

Nigel Wrench, BBC, UK

Kate Shindle, 1998 Miss America

Shreedhar Rajan, India

Georgia Franklin, MTV, UK

Frederick Edelmann, Le Monde, France

Nobby Gilmore, McGill Centre for Medicine, Ethics and Law, McGill University, Canada

SKILLS BUILDING WORKSHOPS

SB 29 Laboratory Techniques for Diagnosis and Management of HIV in Resource-Poor Settings

Venue: Room E
Time: 11.00–14.30

What low technology laboratory techniques exist for clinical diagnosis and management of HIV in primary health care settings? Laboratory specialists will discuss methods that could be used in resource-poor settings. Participants will explore training, equipment, and other needs that would be required in order to develop the technologies presented in their country/region.

Facilitated by: Sharon Cassol, University of Toronto, Canada; Peter Ndumbe, University of Yaoundé, Cameroon; Oliviero Varnier, University of Genova, Italy

SB 30 Desarrollo de programas de nutrición en comunidades de recursos limitados (en español)

Venue: Room F
Time: 11.00–14.30

Para muchos de las personas que viven con el VIH/SIDA, la nutrición es la única terapia disponible. Los participantes estudiarán las estrategias prácticas para crear programas de nutrición viables con el objetivo de cubrir las necesidades de las personas que viven con el VIH/SIDA que viven en comunidades de recursos limitados. Este taller es recomendable a todas las personas con el VIH/SIDA as como a educadores y a personal sanitario.

Impartido por: Rosa Donahue, Switzerland; Raphael Mazin, Pan American Health Organisation

SB 31 Advocacy: How to Influence Leaders in Asia to Take Action

P

Venue: Room G
Time: 11.00–14.30

HIV/AIDS prevention, care and treatment strategies can only have lasting effect if the political leaders in our countries take strong positions of authority. In addition, leadership in the response to HIV/AIDS has to be built on compassion and responsibility. How do you influence leaders to take action or to change their current attitudes about the epidemic? In this workshop, participants will look at a variety of ways of influencing leadership in their country. This workshop is best suited for those who are interested in advocacy and policy (both national- and state-level).

Facilitated by: Bai Bagasao, UNAIDS, Switzerland; Shouket Ali, Pakistan AIDS Prevention Society, Pakistan; Geeta Sethi, UNDP Regional Project on HIV and Development, India

SB 32 Basic Evaluation Techniques for Programmes and Organisations

Venue: Room H
Time: 11.00–14.30

Evaluation helps project staff understand and respond to programme and organisational weaknesses, as well as highlight organisational effectiveness and programme impact. This workshop will introduce basic techniques of evaluation. Through the use of case studies, participants will develop an evaluation strategy and understand how to relate evaluation results to both improve their programmes and respond to donor demands. This workshop is aimed at those wanting to learn basic evaluation techniques.

Facilitated by: Kamane Hapugalle, Alliance, Sri Lanka; Ruth Gunn Mota, Public Health Institute, USA; Timothy Frasca, Corporacion Chilena de Prevencion del Sida, Chile; Penny Bardsley, Argyl and Bute NHS Trust, UK

JULY
1

SKILLS BUILDING WORKSHOPS

SB 33 Comment orienter les décideurs africains vers une politique d'action (en français) P

Venue: Room I
Time: 11.00–14.30

Les campagnes de prévention du VIH/sida, les soins et les stratégies de traitement ne peuvent avoir un effet durable que si les autorités politiques prennent des décisions claires et fermes. Cependant, il faut que les décisions politiques faisant face au VIH/sida soient fondées sur la compassion et la responsabilité. Comment faire, donc, pour orienter les décideurs vers une politique d'action, voire changer leurs dispositions du moment envers l'épidémie? Cet atelier permettra aux participants d'examiner un nombre de façons différentes pour exercer de l'influence sur les autorités politiques de leurs pays. C'est pourquoi cet atelier intéressera particulièrement les personnes motivées par le militantisme et la pression politiques.
Dirigé par: Ron MacInnis, National Council for International Health, USA; As Sy, UNAIDS, South Africa/Senegal

SB 34 IT Friends: How to Provide Peer-to-Peer Support with Electronic Networks

Venue: Room K
Time: 11.00–14.30

This module is for participants familiar with the use of E-mail and the Internet, and will identify and equip potential peer trainers in the South.
Coordinated by: Francisco Mingorance; Tim France and Norbert Ayer, Fondation du Présent, Switzerland; M. David Haery, Sida Info Doc Suisse, Switzerland

SB 35 Utilisation de la formation interactive (en français)

Venue: Room E
Time: 15.00–18.30

Comment faire pour transmettre des informations techniques ou scientifiques à des personnes qui comme vous sont des éducateurs, des parents ou des travailleurs communautaires sans pour autant recourir à des méthodes ennuyeuses? Comment faire pour intéresser des décideurs politiques, un conseil paroissial ou bien un comité d'école à des statistiques ou des résultats de recherche? Comment amener un auditoire à se forger sa propre compréhension d'une question complexe? Dans le cadre de cet atelier pratique, comprenant des études de cas et des exemples de plans de formation, les participants apprendront et partageront des techniques interactives qui leur permettront de faire passer des informations de manière à motiver et stimuler leur auditoire. Cet atelier est destiné aux éducateurs, formateurs, scientifiques et aux agents communautaires ayant besoin de communiquer des informations ou de faciliter une discussion autour de questions complexes.
Dirigé par: Moustapha Gueye, ENDA Santé, Senegal; Juan Jacobo Hernandez, Colectivo Sol, Mexico

SB 36 Building Strategic Alliances to Help Sustain Programme and Organisational Impact

Venue: Room F
Time: 15.00–18.30

Most organisations face financial constraints. Although donor funding may be available to start a programme what happens when a project changes, or the funding decreases or ends? A rising demand for funding for both prevention and care programmes has emphasised the need to assess existing patterns of resource use and to explore alternative ways of sustaining programmes. One way organisations can work towards sustaining effective programmes is by building alliances, or actively collaborating with other organisations, not only NGOs and donors but the private sector, church, local and national government. This workshop will focus on helping participants plan a strategy to develop working relationships/alliances.
Facilitated by: Evelyn Gacad, Philippines HIV/AIDS NGO Support Program, Philippines; Supanya Lamsam, Int. HIV/AIDS Alliance, Thailand; Sarah Lee, Int. HIV/AIDS Alliance, U.K; Geoff Manthey, UNAIDS, Philippines/Australia

SB 37 Extending Community Prevention and Care Programmes to Incorporate Orphan Responses Y

Venue: Room G
Time: 15.00–18.30

As AIDS continues to devastate families and communities, planning and responding to the needs of children orphaned by AIDS is necessary. Join us to discuss how to plan and integrate programmes to support orphans into existing community HIV prevention and care activities. This workshop is aimed at those working in HIV prevention and care.
Facilitated by: Ravinder Kathuria, University of Zambia, Zambia; Sophia Mukaso-Monico, TASO, Uganda

SB 38 Harm Reduction for Injecting Drug Use in Eastern Europe

Venue: Room H
Time: 15.00–18.30

Injecting drug use is a significant mode of transmission of HIV and other blood-borne viruses in many parts of the world. This workshop will draw on participants' experience and use case studies to explore how to establish and sustain innovative programmes that meet the needs of injecting drug users (IDUs). It is aimed at those working with IDUs, and programme and policy designers.
Facilitated by: Annie Madden, NSW Users and AIDS Association, Australia; Palani Narayanan, Asian Harm Reduction Network, Malaysia; Lucy Platt, AIDS InfoShare, Russia

SB 39 Gestión sindrómica de las ETS (en español)

Venue: Room I
Time: 15.00–18.30

En contextos de recursos limitados, la gestión sindrómica de los casos es una manera práctica de controlar las enfermedades transmisibles sexualmente. Los participantes acompañan los problemas que conlleva la implementación de un tratamiento sindrómico, se ayudarán mutuamente a encontrar posibles soluciones y desarrollarán una documentación sistemática de casos que pueden ser útiles en el diagnóstico y en las guías de tratamiento. Esta sesión está dirigida a personal clínico.
Impartido por: Antonio Gerbase, WHO, Switzerland; Fernando Zacarias, Pan American Health Organisation; Jorge Sanchez, National AIDS Control Programme, Peru; Patty Garcia, National AIDS Control Programme, Peru

SB 40 Amigos IT: cómo proporcionar apoyo mutuo a través de la red electrónica (en español)

Venue: Room K
Time: 15.00–18.30

Este módulo está dirigido a los participantes que ya están familiarizados con el correo electrónico e Internet. Servirá para localizar posibles capacitadores paritarios en el sur y dotarles del equipo necesario.
Coordinado por: Francisco Mingorance; Tim France; Norbert Ayer and Fondation du Présent, Switzerland; M. David Haery, Sida Info Doc Suisse, Switzerland